Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor
Smeesters, C.; Chaland, P.; Giroux, L.; Moutquin, J.M.; Etienne, P.; Douglas, F.; Corman, J.; St-Louis, G.; Daloze, P.
Transplantation Proceedings 20(2 Suppl. 2): 663-669
1988
ISSN/ISBN: 0041-1345 PMID: 3163209 Document Number: 320009
Document emailed within 1 workday
Related Documents
Ohsugi, S. 1986: Experimental study on the prevention of vasospasm following subarachnoid hemorrhage by a thromboxane A2 synthetase inhibitor, OKY-046 Nihon Geka Hokan. Archiv für Japanische Chirurgie 55(2): 297-305Nakayama, D.; Ikeda, T. 1988: Effect of OKY-046, a thromboxane synthetase inhibitor, on renal thromboxane synthesis in spontaneously hypertensive rat Nihon Jinzo Gakkai Shi 30(1): 79-84
Chiabrando, C.; Broggini, M.; Castelli, M.G.; Cozzi, E.; Castagnoli, M.N.; Donelli, M.G.; Garattini, S.; Giavazzi, R.; Fanelli, R. 1987: Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor Cancer Research 47(4): 988-991
Sills, T.; Heptinstall, S. 1986: Effects of a thromboxane synthetase inhibitor and a cAMP phosphodiesterase inhibitor, singly and in combination, on platelet behaviour Thrombosis and Haemostasis 55(3): 305-308
Basevich, V.V.; Mevkh, A.T.; Varfolomeev, S.D. 1984: Kinetic mechanisms of enzyme activity of the thromboxane synthetase system. Thromboxane synthetase of human platelets Biokhimiia 49(9): 1538-1545
Machida, K.; Takagi, K.; Horiba, M. 1996: Thromboxane A2 synthetase inhibitor in asthma therapy Nihon Rinsho. Japanese Journal of Clinical Medicine 54(11): 3034-3039
Okamoto, S.; Yonekawa, Y.; Handa, H.; Handa, Y.; Uemura, Y.; Yano, I.; Toyoshima, M.; Iwatsuji, K.; Teraura, T.; Yamagata, S. 1986: Treatment of occlusive cerebrovascular disease with a selective thromboxane A2 synthetase inhibitor Nihon Geka Hokan. Archiv für Japanische Chirurgie 55(1): 251-259
Niwa, T.; Maeda, K.; Shibata, M.; Yamada, K. 1988: Clinical effects of selective thromboxane A2 synthetase inhibitor in patients with nephrotic syndrome Clinical Nephrology 30(5): 276-281
Fomsgaard, J.S.; Kim, Y.D.; Burke, T.A.; Viswanathan, T.; Schaffer, A.V.; Peppard, J.; Douglas, F.L.; Danchak, M.; Myers, A.K. 1992: Comparison of thromboxane synthetase inhibitor and methylprednisolone effects on protamine responses in dogs Anesthesia and Analgesia 74(1): 38-43
Grauer, G.F.; Frisbie, D.D.; Longhofer, S.L.; Cooley, A.J. 1992: Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs American Journal of Veterinary Research 53(5): 808-813
Ennis, C.; Granger, S.E.; Middlefell, V.C.; Philpot, M.E.; Shepperson, N.B. 1989: Pharmacologic effects of Wy 27569: a combined calcium channel blocker and thromboxane synthetase inhibitor Journal of Cardiovascular Pharmacology 13(4): 511-519
Ogawa, T.; Hieda, N.; Sugiyama, S.; Toki, Y.; Ito, T.; Ogawa, K.; Satake, T.; Ozawa, T. 1988: Effect of a novel thromboxane A2 synthetase inhibitor on ischemia-induced mitochondrial dysfunction in canine hearts Arzneimittel-Forschung 38(2): 228-230
Murayama, K.; Kasai, H.; Adachi, T.; Utsunomiya, O.; Ouchi, H. 1983: Comparative study of prostaglandin I2 (PG I2) and thromboxane A2 (TXA2) synthetase inhibitor (OKY-1581) on hemodynamics in pregnant dogs Nihon Sanka Fujinka Gakkai Zasshi 35(3): 344-350
Simpson, P.J.; Smith, C.B.; Rosenthal, G.; Lucchesi, B.R. 1986: Reduction in the incidence of thrombosis by the thromboxane synthetase inhibitor CGS 13080 in a canine model of coronary artery injury Journal of Pharmacology and Experimental Therapeutics 238(2): 497-501
Shimizu, K.; Kobayashi, J.; Iwanaga, T.; Kuratomi, Y.; Kitamura, S. 1989: Effects of thromboxane A2 synthetase inhibitor, DP-1904 on the action of vasoactive substances in rabbit blood vessel smooth muscle preparations Nihon Kyobu Shikkan Gakkai Zasshi 27(5): 591-596
Nizankowski, R.; Krzanowski, M.; Musiał, J.; Szczeklik, A. 1991: Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension Polski Tygodnik Lekarski 46(1-3): 18-21
Makowka, L.; Lopatin, W.; Gilas, T.; Falk, J.; Phillips, M.J.; Falk, R. 1986: Prevention of cyclosporine (CyA) nephrotoxicity by synthetic prostaglandins Clinical Nephrology 25 Suppl. 1: S89-S94
Ishine, N.; Yagi, T.; Ishikawa, T.; Sasaki, H.; Nakagawa, K.; Tanaka, N. 1997: Hemodynamic analysis of post-reperfusion syndrome and the effect of preventing this syndrome using thromboxane A2 synthetase inhibitor (OKY-046) in swine liver transplantation Transplantation Proceedings 29(1-2): 378-381
De Clerck, F.; Beetens, J.; de Chaffoy de Courcelles, D.; Vercammen, E.; Freyne, E.; Janssen, P.A. 1989: R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule Progress in Clinical and Biological Research 301: 567-572
Simić-Ogrizović, S.; Djukanović, L.; Golubović, M.; DimitrijevićZ; Mimić-Oka, J.; Simić, T. 1994: Significance of laboratory tests for differential diagnosis of acute renal allograft rejection and acute cyclosporine nephrotoxicity Srpski Arhiv Za Celokupno Lekarstvo 122(5-6): 133-136